| Recruiting | Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatme NCT07389980 | Yeungnam University College of Medicine | Phase 3 |
| Recruiting | Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Ch NCT06709339 | Association for Innovation and Biomedical Research on Light and Image | Phase 4 |
| Completed | Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV NCT05662943 | Kim's Eye Hospital | — |
| Completed | Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatme NCT03941587 | Singapore National Eye Centre | N/A |
| Unknown | Clinical Implication of Aflibercept in PCV Treatment in China NCT05639660 | Peking Union Medical College Hospital | — |
| Unknown | Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept NCT04707027 | Chiang Mai University | N/A |
| Unknown | Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculo NCT04380974 | Xiaodong Sun | Phase 4 |
| Unknown | Biomarkers of Common Eye Diseases NCT04101604 | Sun Yat-sen University | — |
| Completed | Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV) NCT03929731 | Singapore National Eye Centre | — |
| Completed | OCTA and Polypoidal Choroidal Vasculopathy NCT04714242 | Federico II University | — |
| Terminated | Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy NCT02769169 | Sun Yat-sen University | Phase 2 / Phase 3 |
| Completed | Conbercept for Polypoidal Choroidal Vasculopathy（START Study） NCT05229237 | Peking Union Medical College Hospital | — |
| Completed | An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy NCT03117634 | Singapore National Eye Centre | Phase 4 |
| Unknown | Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases NCT03128463 | Xun Xu | — |
| Completed | Initial Versus Delayed PDT Combination With Conbercept in PCV NCT02821520 | The Eye Hospital of Wenzhou Medical University | Phase 4 |
| Unknown | Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy NCT02976194 | Pusan National University Hospital | Phase 4 |
| Unknown | Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers NCT02815176 | Samsung Medical Center | — |
| Completed | Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal A NCT02495181 | Association for Innovation and Biomedical Research on Light and Image | Phase 4 |
| Unknown | Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: P NCT02597855 | Yeungnam University College of Medicine | — |
| Recruiting | OCT in Rare Chorioretinal Diseases NCT02141308 | Oregon Health and Science University | — |
| Completed | Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment NCT02381730 | Fondation Ophtalmologique Adolphe de Rothschild | N/A |
| Completed | Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy NCT01950741 | Pusan National University Hospital | Phase 4 |
| Completed | Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Eithe NCT01846273 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation NCT01871376 | Gregg T. Kokame, MD | Phase 4 |
| Completed | Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN NCT03459144 | Sun Yat-sen University | N/A |
| Completed | Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy NCT01469156 | Southeast Retina Center, Georgia | Phase 1 / Phase 2 |
| Unknown | Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynam NCT01360151 | Seoul St. Mary's Hospital | N/A |
| Unknown | Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy NCT01248117 | Retina Consultants of Hawaii | Phase 1 / Phase 2 |
| Completed | Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibiz NCT01884597 | Hawaii Pacific Health | Phase 1 / Phase 2 |
| Completed | Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculop NCT01023295 | Mateon Therapeutics | Phase 2 |
| Completed | Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Cho NCT00674323 | Novartis | Phase 4 |
| Completed | Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs NCT01271426 | Nihon University | — |
| Completed | Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Ma NCT00470977 | Manhattan Eye, Ear & Throat Hospital | Phase 1 / Phase 2 |
| Completed | Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) NCT00424710 | Hawaii Pacific Health | Phase 1 |
| Unknown | Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy NCT00344617 | Singapore National Eye Centre | Phase 3 |
| Completed | Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy NCT00837330 | Southeast Retina Center, Georgia | Phase 1 / Phase 2 |
| Unknown | Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy NCT00383812 | Asan Medical Center | N/A |